12:00 AM
Sep 01, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tysabri natalizumab regulatory update

FDA informed healthcare professionals of 2 previously reported cases of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS) receiving Tysabri natalizumab monotherapy in the EU. Biogen Idec and partner Elan reported the cases in an SEC...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >